Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tandem Diabetes Care ( (TNDM) ) has shared an update.
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures advanced automated insulin delivery systems, including the Tandem Mobi and t:slim X2 pumps with Control-IQ+ hybrid closed-loop technology. Based in San Diego, the company targets people requiring intensive insulin therapy, along with their caregivers and healthcare providers, in the diabetes devices market.
On February 23, 2026, Tandem announced a proposed private placement of $200 million in Convertible Senior Notes due 2032, with an option for an additional $30 million, aimed at qualified institutional buyers under Rule 144A. The company plans to use proceeds to fund capped call transactions to limit dilution from note conversions and for general corporate purposes, while acknowledging that associated hedging and derivative activity may affect the market prices of its stock and the notes over time.
The most recent analyst rating on (TNDM) stock is a Sell with a $27.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Spark’s Take on TNDM Stock
According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.
The score is held down primarily by weak financial quality (ongoing losses, higher leverage, and renewed cash burn). Technicals also remain bearish despite oversold signals. These negatives are partly offset by a more positive earnings outlook and improving margins, but near-term headwinds from the PayGo transition limit confidence.
To see Spark’s full report on TNDM stock, click here.
More about Tandem Diabetes Care
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems aimed at reducing the burden of diabetes management. Its pump portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ+ advanced hybrid closed-loop technology, and the company is headquartered in San Diego, Calif.
Tandem focuses on providing innovative insulin pump solutions for people living with diabetes, their caregivers, and healthcare providers, leveraging proprietary technology to improve glycemic control. The company markets its offerings primarily to patients requiring intensive insulin therapy and seeks to expand its presence in the diabetes devices segment through both product innovation and strategic investments.
On February 23, 2026, Tandem Diabetes Care announced a proposed private placement of $200 million in Convertible Senior Notes due 2032, with an option for initial purchasers to buy an additional $30 million, in a deal targeted at qualified institutional buyers under Rule 144A. The notes will be unsecured, pay semiannual interest, and be convertible into cash, common stock, or a combination at Tandem’s election, with key economic terms such as interest rate and conversion rate to be set at pricing.
The company plans to use the net proceeds primarily to fund capped call transactions designed to mitigate dilution from potential note conversions, with remaining funds earmarked for general corporate purposes including possible acquisitions, strategic investments, and capital spending. Tandem expects related hedging and derivative activities by option counterparties around pricing and over the life of the notes could influence the trading dynamics and market price of its common stock and the notes, affecting how and when investors choose to convert.
Average Trading Volume: 1,833,606
Technical Sentiment Signal: Buy
Current Market Cap: $1.84B
Find detailed analytics on TNDM stock on TipRanks’ Stock Analysis page.